IndraLab
Statements
sparser
"Broader applicability of PRC2 inhibition to the treatment of other cancers is supported by the general prevalence of mutations in other chromatin-associated proteins that perturb the balance of activities regulating H3K27me3, including components of the SWI/SNF chromatin remodeling complex and the BAP1 H2A deubiquitinase complex ( xref )."